Topical issues concerning treatment of intracellular bacterial pathogens in children
<p< <b<M.S. Savenkova<sup<1,2</sup<, M.P. Savenkov<sup<1</sup<</b< </p< <p< <b<<sup<1</sup<Pirogov Russian National Research Medical University, Moscow, Russian Federation</b< </p< <p< <b<<sup<2</sup<Morozov Children’s City Clinical Hospital, Moscow, Russian Federation</b< </p< <p< <i<The article considers the issues of pharmacodynamics, clinical efficacy and safety of macrolide antibiotics. It also discusses the development of microorganisms resistance to macrolides. A number of studies in vivo and in vitro on various cellular and animal models have shown that macrolides have anti-inflammatory and immunomodulatory effects. The presence of these effects in macrolides may be especially relevant during the period of increasing incidence of influenza and the new COVID-19 coronavirus infection. It is known that the severity of viral infections is associated with the release of proinflammatory cytokines. Macrolides change the entire inflammatory response cascade by weakening the excess production of cytokines. Besides, macrolides can affect the activity of phagocytes, changing their function, including chemotaxis, phagocytosis, destroying bacteria and viruses. Earlier it was reported that macrolides (in particular, clarithromycin) can interfere with the replication cycle of the influenza virus, thus leading to its production inhibition by intracellular proteolysis of hemagglutinin. One of the commonly prescribed drugs in this group is clarithromycin. The article summarizes the literature data and presents the materials of our own clinical observations on the clarithromycin treatment of children with intracellular bacterial pathogens, the causative agents of which are Mycoplasma pneumoniae and Chlamydia pneumoniae.</i< </p< <p< <i<<b<Keywords</b<: macrolides, clarithromycin, intracellular bacterial pathogens, children, antibacterial therapy.</i< </p< <p< <i<<b<For citation: </b<Savenkova M.S., Savenkov M.P. Topical issues concerning treatment of intracellular bacterial pathogens in children. Russian Journal of Woman and Child Health. 2020;3(4):326–335. DOI: 10.32364/2618-8430-2020-3-4-326-335.</i< </p<.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
РМЖ. Мать и дитя - 3(2020), 4 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
M.S. Savenkova [VerfasserIn] |
|---|
| Links: |
doaj.org [kostenfrei] |
|---|
| Themen: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ00235988X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ00235988X | ||
| 003 | DE-627 | ||
| 005 | 20240413170203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2020 xx |||||o 00| ||rus c | ||
| 035 | |a (DE-627)DOAJ00235988X | ||
| 035 | |a (DE-599)DOAJ6835bfe3cfda48faba9bcba35664defa | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RJ1-570 | |
| 050 | 0 | |a RG1-991 | |
| 100 | 0 | |a M.S. Savenkova |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Topical issues concerning treatment of intracellular bacterial pathogens in children |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a <p< <b<M.S. Savenkova<sup<1,2</sup<, M.P. Savenkov<sup<1</sup<</b< </p< <p< <b<<sup<1</sup<Pirogov Russian National Research Medical University, Moscow, Russian Federation</b< </p< <p< <b<<sup<2</sup<Morozov Children’s City Clinical Hospital, Moscow, Russian Federation</b< </p< <p< <i<The article considers the issues of pharmacodynamics, clinical efficacy and safety of macrolide antibiotics. It also discusses the development of microorganisms resistance to macrolides. A number of studies in vivo and in vitro on various cellular and animal models have shown that macrolides have anti-inflammatory and immunomodulatory effects. The presence of these effects in macrolides may be especially relevant during the period of increasing incidence of influenza and the new COVID-19 coronavirus infection. It is known that the severity of viral infections is associated with the release of proinflammatory cytokines. Macrolides change the entire inflammatory response cascade by weakening the excess production of cytokines. Besides, macrolides can affect the activity of phagocytes, changing their function, including chemotaxis, phagocytosis, destroying bacteria and viruses. Earlier it was reported that macrolides (in particular, clarithromycin) can interfere with the replication cycle of the influenza virus, thus leading to its production inhibition by intracellular proteolysis of hemagglutinin. One of the commonly prescribed drugs in this group is clarithromycin. The article summarizes the literature data and presents the materials of our own clinical observations on the clarithromycin treatment of children with intracellular bacterial pathogens, the causative agents of which are Mycoplasma pneumoniae and Chlamydia pneumoniae.</i< </p< <p< <i<<b<Keywords</b<: macrolides, clarithromycin, intracellular bacterial pathogens, children, antibacterial therapy.</i< </p< <p< <i<<b<For citation: </b<Savenkova M.S., Savenkov M.P. Topical issues concerning treatment of intracellular bacterial pathogens in children. Russian Journal of Woman and Child Health. 2020;3(4):326–335. DOI: 10.32364/2618-8430-2020-3-4-326-335.</i< </p< | ||
| 653 | 0 | |a Pediatrics | |
| 653 | 0 | |a Gynecology and obstetrics | |
| 700 | 0 | |a M.P. Savenkov |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t РМЖ. Мать и дитя |d LCC «Medicine-Inform», 2020 |g 3(2020), 4 |w (DE-627)DOAJ078631165 |x 26867184 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2020 |g number:4 |
| 856 | 4 | 0 | |u https://doaj.org/article/6835bfe3cfda48faba9bcba35664defa |z kostenfrei |
| 856 | 4 | 0 | |u http://wchjournal.com/upload/iblock/30f/30f9023510e79b86f5704688ee847042.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2618-8430 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2686-7184 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2020 |e 4 | ||